Alimera Sciences To Release First Quarter 2014 Results

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ATLANTA, May 1, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (“Alimera”), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it will release its first quarter of fiscal year 2014 financial results after the market close on Thursday, May 8, 2014. An investor conference call will follow on the same day at 4:30 p.m. ET.

The conference call will be hosted by Dan Myers, President and Chief Executive Officer, and Rick Eiswirth, Chief Operating Officer and Chief Financial Officer.

To participate in the call, please dial (877) 369-6586 (U.S. and Canada) or (253) 237-1165 (international). A live webcast will be available on the Investor Relations section of the corporate website at http://www.alimerasciences.com.

A replay of the conference call will be available beginning May 8, 2014 at 7:30 p.m. ET and ending on May 16, 2014 by dialing (855) 859-2056 (U.S. and Canada) or (404) 537-3406 (international), Conference ID Number: 41171987. A replay of the webcast will also be available on the corporate website.

About Alimera Sciences, Inc.

Alimera Sciences, Inc., headquartered in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Alimera’s European operations are conducted from London by its wholly-owned subsidiary, Alimera Sciences Limited.

Investor Contact:

ICR, LLC

John Mills

310-954-1105

John.Mills@icrinc.com


SOURCE Alimera Sciences, Inc.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC